Parallel (the “Company”), one of the largest privately-held multi-state cannabis operators in the United States (U.S.), announced today that it commenced sales of medical cannabis products in Pennsylvania through the opening of its first goodblend™ retail branded store in Pittsburgh, with the intent to open a second store in Erie in the coming weeks. goodblend™ is a new cannabis cultivator, producer, and retailer in Pennsylvania.
“This is another milestone for Parallel, as we are now serving the rapidly growing needs of medical cannabis patients in the Commonwealth,” said William “Beau” Wrigley, Jr., Chief Executive Officer and Chairman of Parallel. “We believe Pennsylvania is an exciting, high-growth cannabis market and we look forward to providing well-being through cannabinoids to patients across Pennsylvania in the years to come.”
Pennsylvania, with almost 13 million residents, is the sixth most populous state in the U.S. The Commonwealth’s Medical Marijuana Program today has approximately 500,000 registered patients and caregivers.
“I couldn’t be more excited for our team to begin serving qualifying patients within goodblend’s approachable retail environment. Our dispensaries are designed to make patients feel comfortable, with expert retail guides ready to answer any questions and help them find the right cannabis products to fit their specific needs,” said Elizabeth (Liz) Conway, Regional President, of Parallel and goodblend Pennsylvania. “For the past few months, we’ve been conducting local job recruitment in addition to having held preparatory informational sessions on expungement in partnership with the Minority Cannabis Business Association (MCBA) to support social equity and economic empowerment in our communities. Now, we welcome community medical patients into our stores.”
The Pittsburgh dispensary is located at 5502 Baum Boulevard in Pittsburgh, Pennsylvania. Regular operating hours will be Monday through Saturday 10:00 a.m. to 8:00 p.m., and Sunday 11:00 a.m. to 6:00 p.m.
To learn more about goodblend™, its store locations, and initial offering of well-known cannabis brands visit pa.goodblend.com. Parallel plans to make a wider array of product offerings available to qualifying patients later in the year.
About goodblend Pennsylvania
goodblend Pennsylvania, a retail brand of Parallel, is one of eight vertically integrated Clinical Registrants in the Commonwealth and was granted a license in partnership with the University of Pittsburgh School of Medicine in August 2020. In addition to opening the retail facilities in Pittsburgh and Erie, goodblend ™ intends to continue to invest in building a cultivation facility. The Clinical Research Partnership with University of Pittsburgh School of Medicine, one of the leading medical research schools in the world, will initially focus on the impact of medicinal cannabis on various symptoms of sickle cell disease and chronic pain.
The goodblend ™ brand reflects Parallel’s intent to lead the way to the future of cannabis by providing its customers with a trusted, consistent, and seamless way for them to connect and learn, and to access innovative, high-quality cannabis products in a variety of form factors and to elicit such a positive experience that they come back again and again. The brand is about welcoming every type of customer and being an approachable source of products and information to support our customers’ well-being. The ethos of goodblend ™ is based on Parallel’s commitment to compliance, quality, innovation, and to be a great employer and local community partner, as well as its actions to improve diversity, inclusivity, and economic empowerment in the cannabis industry. To learn more about goodblend, visit pa.goodblend.com or on Facebook and Twitter.
Parallel is one of the largest privately held, vertically integrated, multi-state cannabis companies in the United States with a mission to pioneer well-being and improve quality of life through cannabinoids. Parallel recently announced that it intends to become a public company through a definitive business combination agreement with Ceres Acquisition Corp. (“Ceres“) (NEO: CERE.U, CERE.WT;OTCQX: CERAF), a special purpose acquisition corporation (SPAC). Parallel has ongoing operations in four medical and adult-use markets under the retail brands of Surterra Wellness in Florida; goodblend in Texas; New England Treatment Access (NETA) in Massachusetts; and The Apothecary Shoppe in Nevada. Parallel also has a license under its goodblend Pennsylvania brand for vertically integrated operations and up to six retail locations, in addition to a medical cannabis research partnership with the University of Pittsburgh School of Medicine. Subject to regulatory approval, Parallel will add Illinois as a sixth market when its announced acquisition of six Windy City Cannabis licenses is complete. Parallel has a diverse portfolio of high quality, proprietary and licensed consumer brands and products including Surterra Wellness, Coral Reefer, Float and Heights. Parallel operates approximately 50 locations nationwide, including 42 retail stores, and cultivation and manufacturing sites. Through its wholly-owned Parallel Biosciences subsidiary, it conducts advanced cannabis science and R&D for new product development in its facilities in Massachusetts, Florida, Texas and a facility in Budapest, Hungary through an exclusive license and partnership. Parallel follows rigorous operations and business practices to ensure the quality, safety, consistency, and efficacy of its products and is building its business by following strong values and putting the well-being of its customers and employees first. Find more information at www.liveparallel.com, or on Instagram and LinkedIn.
In connection with the proposed transaction with Ceres, that, if completed, would result in Parallel becoming a public company (Transaction), Ceres is expected to file a Form S-4 with the U.S. Securities Exchange Commission (SEC). Ceres and Parallel urge investors, stockholders and other interested persons to read, when available, the Form S-4, preliminary and final non-offering prospectus, including any amendments thereto, the Ceres special meeting circular, as well as other documents to be filed with the SEC and documents to be filed with Canadian securities regulatory authorities in connection with the Transaction, as these materials will contain important information about Ceres, Parallel, the combined public company and the Transaction. Ceres also has, and will, file other documents regarding the Transaction with the SEC. Investors and security holders will be able to obtain free copies of the registration statement and all other relevant documents filed or that will be filed with the SEC by Ceres through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by Ceres may be obtained free of charge from Ceres’ website at www.ceresacquisition.comor by written request to Ceres at Ceres Acquisition Corp., 1925 Century Park East, Suite 1700, Los Angeles, California, United States 90067.